Much debate surrounds the utility of CYP2C19*2 genotyping in patients receiving clopidogrel after coronary artery stenting. The effectiveness of its use in a point-of-care setting has now been examined and, given the substantial incremental suppression of platelet reactivity achieved, its routine use might soon be a reality.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Roberts, J. D. et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet http://dx.doi.org/10.1016/S0140-6736(12)60161-5.
Mega, J. L. et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304, 1821–1830 (2010).
Price, M. J. et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur. Heart J. 29, 992–1000 (2008).
Breet, N. J. et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303, 754–762 (2010).
Bonello, L. et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J. Am. Coll. Cardiol. 56, 919–933 (2010).
Price, M. J. et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 124, 1132–1137 (2011).
Holmes, M. V., Perel, P., Shah, T., Hingorani, A. D. & Casas, J. P. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 306, 2704–2714 (2011).
Patay, B. A. & Topol, E. J. The unmet need of education in genomic medicine. Am. J. Med. 125, 5–6 (2012).
McCormack, M. et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med. 364, 1134–1143 (2011).
Chen, P. et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N. Engl. J. Med. 364, 1126–1133 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
P. M. Barrett declares that he has received unrestricted grants or research support from Daiichi Sankyo and Menarini. E. J. Topol declares that he is a consultant for Quest Diagnostics.
Rights and permissions
About this article
Cite this article
Barrett, P., Topol, E. Point-of-care genetic testing—a new frontier explored. Nat Rev Cardiol 9, 315–316 (2012). https://doi.org/10.1038/nrcardio.2012.63
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2012.63
This article is cited by
-
Inflammatory processes in cardiovascular disease: a route to targeted therapies
Nature Reviews Cardiology (2017)